Effects of paclitaxel and nuclear factor NF-κB inhibitor in thyroid cancer tumors in vivo

1Pushkarev, VM, 1Kovzun, OI, 1Pushkarev, VV, 1Tronko, MD
1V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv
Dopov. Nac. akad. nauk Ukr. 2014, 5:164-167
https://doi.org/10.15407/dopovidi2014.05.164
Section: Medicine
Language: Ukrainian
Abstract: 

Nuclear factor kappa B (NF-κB) inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) enhances the therapeutic effect of paclitaxel on tumors formed by the xenotransplantation of anaplastic thyroid carcinoma FRO cells. In animals treated with paclitaxel and NF-κB inhibitor, a reduction in the tumor volume was observed, which is significantly different from the effects of each of the compounds in particular. Thus, the combined use of paclitaxel and NF-κB inhibitor is a promising strategy for further preclinical studies for developing the new chemotherapeutic approaches for the anaplastic thyroid cancer treatment.

Keywords: inhibitor, nuclear factor, paclitaxel, thyroid cancer tumors
References: 

1. Jordan M. A., Wilson L. Nat. Rev. Canc., 2004, 4: 253–265. https://doi.org/10.1038/nrc1317
2. Pushkarev V. M., Starenki D. V., Saenko V. A. et al. Endocrinology, 2004, 145, No. 7: 3143–3152. https://doi.org/10.1210/en.2004-0127
3. Tronko M. D., Pushkarev V. V., Kovzun O. I., Pushkarev V. M. Endokrynologiia, 2013, 18, No. 2: 78-91 (in Ukrainian).
4. Orlowski R. Z., Baldwin A. S., jr. Trends Mol. Med., 2002, 8, No. 8: 385–389. https://doi.org/10.1016/S1471-4914(02)02375-4
5. Liptay S., Weber C. K., Ludwig L. et al. Int. J. Cancer., 2003, 105: 735–746. https://doi.org/10.1002/ijc.11081
6. Karin M. Cell Res., 2008, 18: 334–342. https://doi.org/10.1038/cr.2008.30
7. Wang H., Cho C. H. Curr. Cancer Drug Targets., 2010, 10, No. 6: 593–599. https://doi.org/10.2174/156800910791859425
8. Pacifico F., Mauro C., Barone C. et al. J. Biol. Chem., 2004, 279, No. 52: 54610–54619. https://doi.org/10.1074/jbc.M403492200
9. Pacifico F., Leonardi A. Mol. Cell. Endocrinol., 2010, 321, No. 1: 29–35. https://doi.org/10.1016/j.mce.2009.10.010
10. Kovzun O. I., Pushkarev V. V. Endokrynologiia, 2005, 10, No. 1: 130–133 (in Ukrainian).
11. Chen W., Li Z., Bai L., Lin Y. Front. Biosci., 2011, 16: 1172–1185. https://doi.org/10.2741/3782
12. Luo J. L., Kamata H., Karin M. J. Clin. Invest., 2005, 115, No. 10: 2625–2632. https://doi.org/10.1172/JCI26322